LENZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
LENZ Therapeutics Inc is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is currently undervalued based on analyst price targets, and the recent selloff appears to be an overreaction to isolated events. The technical indicators, options sentiment, and financial improvements support a positive outlook for long-term growth.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 58.365, suggesting no overbought or oversold conditions. However, moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a longer-term downtrend. Key resistance levels are at 13.445 and 13.962, with support at 12.608 and 11.772.
Analysts maintain a Buy rating with high price targets ($35-$56), indicating significant upside potential.
The recent selloff is deemed an overreaction by analysts, with no substantial evidence linking adverse events to the company's product.
Financial performance shows improvement in net income and EPS, with a 63.49% YoY increase in net income and a 55.26% YoY increase in EPS.
Bearish moving averages indicate a longer-term downtrend.
No recent news or congress trading data to provide additional support for immediate momentum.
In Q3 2025, revenue remained flat YoY at $12.5M, but net income improved significantly by 63.49% YoY to -$16.7M. EPS also improved by 55.26% YoY to -0.59. Gross margin remained strong at 100%.
Analysts are bullish on LENZ with Buy ratings and price targets ranging from $35 to $56. Recent updates suggest optimism about the company's product uptake despite a slower-than-expected launch ramp. Analysts view the recent selloff as an overreaction to isolated adverse events.
